The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP).
 
Riha Vaidya
No Relationships to Disclose
 
Joseph M. Unger
No Relationships to Disclose
 
Lu Qian
No Relationships to Disclose
 
Katherine Minichiello
No Relationships to Disclose
 
Roy S. Herbst
Leadership - Immunocore; Junshi Pharmaceuticals
Consulting or Advisory Role - Abbvie; ARMO Biosciences; AstraZeneca; Bayer; Biodesix; Bolt Biotherapeutics; Bristol-Myers Squibb; Candel Therapeutics; Checkpoint Therapeutics; Cybrexa Therapeutics; DynamiCure Biotechnology; eFFECTOR Therapeutics; EMD Serono; Foundation Medicine; Genentech/Roche; Genmab; Gilead/Forty Seven; Halozyme; Heat Biologics; HiberCell; I-Mab; Immune-Onc Therapeutics; Infinity Pharmaceuticals; Johnson and Johnson; Junshi Pharmaceuticals; Lilly; Loxo; Merck; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Ocean Biomedical; OncoCyte; Oncternal Therapeutics; Pfizer; Refactor Health; Ribon Therapeutics; Sanofi; Seagen; Shire; Spectrum Pharmaceuticals; STCube Pharmaceuticals Inc.; Symphogen; Takeda; TESARO; Tocagen; Ventana Medical Systems; WindMIL; Xencor
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
 
David R. Gandara
Honoraria - Amgen; Merck
Consulting or Advisory Role - Adagene (Inst); AstraZeneca (Inst); Daiichi Sankyo Alliance; Guardant Health (Inst); Guardant Health (Inst); IO Biotech (Inst); Lilly; Novartis; Ocean Genomics (Inst); OncoCyte (Inst); OncoHost (Inst); Roche/Genentech (Inst); Sanofi
Research Funding - Amgen (Inst); AstraZeneca (Inst); Genentech (Inst); Merck (Inst)
 
Joel W. Neal
Honoraria - Biomedical Learning Institute; Clinical Care Options; CME Matters; Medscape; MJH Life Sciences; Peerview; Prime Oncology; Projects in Knowledge; Research to Practice; Rockpointe CME
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Calithera Biosciences; D2G Oncology; Exelixis; Genentech/Roche; Iovance Biotherapeutics; Jounce Therapeutics; Lilly; Natera; Regeneron; Sanofi/Regeneron; Surface Oncology; Surface Oncology; Takeda; Turning Point Therapeutics
Research Funding - AbbVie (Inst); Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties
 
Ticiana Leal
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Lilly; Daiichi-Sankyo; Eisai; EMD Serono; EMD Serono; Genentech; Janssen; Jazz Pharmaceuticals; Lilly; Merck; Merck; Mirati Therapeutics; Novocure; Takeda
 
Jyoti D. Patel
Consulting or Advisory Role - Abbvie; AstraZeneca; Genentech; Lilly; Takeda Science Foundation
Research Funding - Bristol-Myers Squibb (Inst)
 
Konstantin H. Dragnev
Research Funding - G1 Therapeutics (Inst); Io Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); PharmaMar (Inst); Roche/Genentech (Inst)
 
Saiama Naheed Waqar
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Hengrui Therapeutics (Inst); Ignyta (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Stem CentRx (Inst); Synermore biologics (Inst); Vertex (Inst); Xcovery (Inst)
 
Martin Joseph Edelman
Stock and Other Ownership Interests - Biomarker Strategies
Consulting or Advisory Role - e-doctor healthcare reviews; Flame Biosciences; Kanaph Therapeutics; Precision Oncology; Proventus Group; Sanofi/Regeneron; WindMIL
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Nektar (Inst); United Therapeutics (Inst); Windmil (Inst)
Patents, Royalties, Other Intellectual Property - Patent application for radiopharmaceutical to treat small cell lung cancer. (Inst)
Travel, Accommodations, Expenses - Nektar
Other Relationship - AstraZeneca/MedImmune; Boehringer Ingelheim; Seagen; Takeda
 
Ellen V. Sigal
Consulting or Advisory Role - EQRx; GRAIL
Travel, Accommodations, Expenses - H3 Biomedicine
 
Stacey Adam
No Relationships to Disclose
 
Shakun M. Malik
No Relationships to Disclose
 
Charles David Blanke
No Relationships to Disclose
 
Michael Leo LeBlanc
Consulting or Advisory Role - Agios
 
Karen Kelly
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Daiichi Sanko; Debiopharm Group; Eisai; EMD Serono; Genentech; Genmab; Janssen; Lilly; Novartis; Regeneron; Sanofi; Takeda; Targeted Oncology
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Meyers Squibb (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Regeneron (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
Travel, Accommodations, Expenses - EMD Serono; Lilly; Novartis; Takeda
 
Mary Weber Redman
No Relationships to Disclose